StoxGlobal Health vs Wockhardt: share price & financials comparison
NSE: MEDANTA vs WOCKPHARMA · Healthcare · as of 13 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Global Health vs Wockhardt at a glance
Global Health (MEDANTA) has a market capitalisation of ₹39,065 Cr, against ₹32,841 Cr for Wockhardt (WOCKPHARMA). Over the past year Wockhardt has returned +48.5%, compared with +16.4% for Global Health. On valuation, Wockhardt trades at a lower P/E of 80.1 versus 98.2. Global Health earns a higher return on equity (9.2% vs 7.9%). Global Health comes out ahead on size, profitability, growth and financial health. Wockhardt comes out ahead on valuation and technicals. Across the scored metrics below, Global Health leads on 8 and Wockhardt on 7. On StoxGud's 10-point checklist, Global Health scores 6/10 and Wockhardt scores 6/10.
| Metric | Global Health | Wockhardt |
|---|---|---|
| Size | ||
| Market cap | ₹39,065 Cr | ₹32,841 Cr |
| Revenue (latest FY) | ₹4,410 Cr | ₹3,373 Cr |
| Net profit (latest FY) | ₹556 Cr | ₹213 Cr |
| Valuation | ||
| P/E | 98.2 | 80.1 |
| P/B | 9.04 | 6.37 |
| Dividend yield | 0.03% | — |
| Profitability | ||
| Return on equity | 9.2% | 7.9% |
| Net profit margin | 7.9% | 10.9% |
| Operating margin | 22.1% | 20.4% |
| Growth | ||
| Revenue growth (YoY) | +33.6% | +23.9% |
| Net profit growth (YoY) | -100.0% | +1.3% |
| Revenue CAGR (multi-year) | +17.9% | +4.5% |
| Financial health | ||
| Debt to equity | 0.16 | 0.42 |
| Momentum | ||
| 1-month return | +13.6% | +2.2% |
| 1-year return | +16.4% | +48.5% |
| 3-year CAGR | +16.9% | +92.3% |
| 5-year CAGR | — | +36.5% |
| 10-year CAGR | — | +11.2% |
| Distance from 52W high | -3.6% | -13.0% |
| Technicals | ||
| RSI (14) | 88 | 74 |
| Price vs 200-day avg | +15.9% | +17.2% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Global Health | Wockhardt |
|---|---|---|
| Price above 50-day average | ✓ | ✗ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✓ | ✓ |
| RSI in healthy 40–70 zone | ✗ | ✗ |
| Positive 1-year return | ✓ | ✓ |
| Return on equity above 15% | ✗ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✗ | ✓ |
| P/E below industry median | ✗ | ✗ |
| Score | 6/10 | 6/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Global Health or Wockhardt?
Global Health has a market cap of ₹39,065 Cr and Wockhardt has a market cap of ₹32,841 Cr as of 13 Nov 2026.
Which has a lower P/E, Global Health or Wockhardt?
Wockhardt has the lower P/E: Global Health trades at 98.2 and Wockhardt at 80.1.
Which gave better returns in the last year, Global Health or Wockhardt?
Wockhardt did better: Global Health returned +16.4% and Wockhardt returned +48.5% over one year.
What is the difference between Global Health and Wockhardt?
Both are NSE-listed companies in Healthcare. Global Health is about 1.2 times the size of Wockhardt by market cap. In the latest financial year Global Health reported revenue of ₹4,410 Cr and Wockhardt ₹3,373 Cr. Operating margin is 22.1% for Global Health and 20.4% for Wockhardt. Debt to equity is 0.16 for Global Health and 0.42 for Wockhardt.
Which is better, Global Health or Wockhardt?
It depends on what you are looking for, and StoxGud does not recommend either stock. On the metrics compared above, Global Health leads on 8 and Wockhardt on 7. Global Health is ahead on size, profitability, growth and financial health. Wockhardt is ahead on valuation and technicals. On StoxGud's rules-based checklist Global Health scores 6/10 and Wockhardt scores 6/10. This is information, not advice: consult a SEBI-registered adviser before investing.